- Report
- February 2025
- 200 Pages
Global
From €4156EUR$4,490USD£3,495GBP
- Report
- May 2025
- 194 Pages
Global
From €5414EUR$5,850USD£4,554GBP
- Report
- January 2025
- 175 Pages
Global
From €4156EUR$4,490USD£3,495GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1388EUR$1,500USD£1,168GBP
- Report
- March 2025
- 180 Pages
Global
From €4165EUR$4,500USD£3,503GBP
- Report
- March 2025
- 180 Pages
Global
From €4165EUR$4,500USD£3,503GBP
- Report
- June 2024
- 54 Pages
Global
From €9251EUR$9,995USD£7,780GBP
- Report
- May 2024
- 137 Pages
Global
From €6015EUR$6,499USD£5,059GBP
- Report
- May 2024
- 130 Pages
Global
From €6015EUR$6,499USD£5,059GBP
- Report
- November 2023
- 145 Pages
Global
From €6942EUR$7,500USD£5,838GBP
- Report
- February 2024
- 180 Pages
Global
From €4599EUR$4,969USD£3,868GBP
- Report
- January 2022
- 115 Pages
Global
From €4396EUR$4,750USD£3,697GBP
- Drug Pipelines
- July 2022
- 53 Pages
Global
From €9251EUR$9,995USD£7,780GBP
- Report
- May 2025
- 50 Pages
Global
From €2453EUR$2,650USD£2,063GBP

Miglustat is a drug used to treat endocrine and metabolic disorders. It is used to treat Gaucher disease type 1, a rare genetic disorder that affects the body's ability to break down and store fat. It is also used to treat Niemann-Pick disease type C, a rare genetic disorder that affects the body's ability to break down and store cholesterol. Miglustat works by inhibiting the enzyme glucosylceramide synthase, which is responsible for the production of glucosylceramide, a molecule that accumulates in the cells of patients with these diseases.
Miglustat is available in both oral and intravenous formulations. It is marketed by several pharmaceutical companies, including Actelion Pharmaceuticals, Sanofi, and Shire. It is also available as a generic drug in some countries.
Companies in the Miglustat market include Actelion Pharmaceuticals, Sanofi, Shire, and generic drug manufacturers. Show Less Read more